読み込み中
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
前日終値
$2.25
+$0.03 · +1.35%
日中の時刻はETです。市場データは遅延する場合があります。
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
日中レンジ
現在 $2.25
52週レンジ
現在 $2.25
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
36
割高
センチメント
49
まちまち
リスク
53
やや高いリスク
モメンタム
79
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
日中レンジ
現在 $2.25
52週レンジ
現在 $2.25
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$9.00
上昇余地（300.00%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI424.66万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM259.54万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF162.47万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO69.42万0.00%180億 USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS45.99万0.00%338.69億 USD0.31%$78.35+0.32%
iShares Micro-Cap ETFIWC31.61万0.02%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM24万0.21%1.17億 USD0.73%$15.9402+0.25%
Invesco RAFI US 1500 Small-Mid ETFPRFZ22.66万0.01%26.52億 USD0.36%$53.16+0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco RAFI US 1500 Small-Mid ETFPRFZAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
